Intranasal administration of adjuvant-combined vaccine protects monkeys from challenge with the highly pathogenic influenza A H5N1 virus.
The effectiveness in cynomolgus macaques of intranasal administration of an influenza A H5N1 pre-pandemic vaccine combined with synthetic double-stranded RNA (polyI/polyC12U) as an adjuvant was examined. The monkeys were immunized with the adjuvant-combined vaccine on weeks 0, 3, and 5, and challenged with the homologous virus 2 weeks after the third immunization. After the second immunization, the immunization induced vaccine-specific salivary IgA and serum IgG antibodies, as detected by ELISA. The serum IgG antibodies present 2 weeks after the third immunization not only had high neutralizing activity against the homologous virus, they also neutralized significantly heterologous influenza A H5N1 viruses. The vaccinated animals were protected completely from the challenge infection with the homologous virus. These results suggest that intranasal immunization with the Double stranded RNA-combined influenza A H5N1 vaccine induce mucosal IgA and serum IgG antibodies which could protect humans from homologous influenza A H5N1 viruses which have a pandemic potential.
Ichinohe
Takeshi
T
Department of Pathology, National Institute of Infectious Diseases, Musashimurayama-shi, Tokyo, Japan.
Ainai
Akira
A
Ami
Yasushi
Y
Nagata
Noriyo
N
Iwata
Naoko
N
Kawaguchi
Akira
A
Suzaki
Yuriko
Y
Odagiri
Takato
T
Tashiro
Masato
M
Takahashi
Hidehiro
H
Strayer
David R
DR
Carter
William A
WA
Chiba
Joe
J
Tamura
Shin-ichi
S
Sata
Tetsutaro
T
Kurata
Takeshi
T
Hasegawa
Hideki
H
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000281:Administration, Intranasal; D000818:Animals; D057134:Antibodies, Neutralizing / Q000032:analysis / Q000097:blood; D000914:Antibodies, Viral / Q000032:analysis / Q000097:blood; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D007117:Immunization, Secondary / Q000379:methods; D007070:Immunoglobulin A / Q000032:analysis; D007074:Immunoglobulin G / Q000097:blood; D053124:Influenza A Virus, H5N1 Subtype / Q000276:immunology* / Q000472:pathogenicity; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000276:immunology*; D008252:Macaca fascicularis; D008297:Male; D009500:Neutralization Tests; D009976:Orthomyxoviridae Infections / Q000517:prevention & control* / Q000821:virology; D012330:RNA, Double-Stranded / Q000008:administration & dosage; D012463:Saliva / Q000276:immunology; D014611:Vaccination / Q000379:methods
D000276:Adjuvants, Immunologic; D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007252:Influenza Vaccines; D012330:RNA, Double-Stranded